DE69434593D1 - Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta - Google Patents

Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta

Info

Publication number: DE69434593D1
Authority: DE; Germany
Prior art keywords: beta; tgf; latent; effective; inhibiting
Prior art date: 1993-08-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69434593T

Other languages

English (en)

Inventor

Joanne E Murphy-Ullrich

David D Roberts

Henry C Krutzsch

Stacey Schultz-Cherry

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

US Department of Health and Human Services

UAB Research Foundation

Original Assignee

US Department of Health and Human Services

UAB Research Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-13

Filing date

1994-08-12

Publication date

2006-02-02

1994-08-12 Application filed by US Department of Health and Human Services, UAB Research Foundation filed Critical US Department of Health and Human Services

2006-02-02 Application granted granted Critical

2006-02-02 Publication of DE69434593D1 publication Critical patent/DE69434593D1/de

2014-08-13 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 18
238000000034 method Methods 0.000 title abstract 6
230000002401 inhibitory effect Effects 0.000 title abstract 5
230000000694 effects Effects 0.000 title abstract 3
230000004936 stimulating effect Effects 0.000 title abstract 2
239000000203 mixture Substances 0.000 title 1
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 17
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 17
108090000765 processed proteins & peptides Proteins 0.000 abstract 5
206010016654 Fibrosis Diseases 0.000 abstract 3
238000006243 chemical reaction Methods 0.000 abstract 3
230000004761 fibrosis Effects 0.000 abstract 3
230000003213 activating effect Effects 0.000 abstract 2
210000002889 endothelial cell Anatomy 0.000 abstract 2
230000029663 wound healing Effects 0.000 abstract 2
206010052428 Wound Diseases 0.000 abstract 1
208000027418 Wounds and injury Diseases 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000010046 negative regulation of endothelial cell proliferation Effects 0.000 abstract 1
230000007170 pathology Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DE69434593T 1993-08-13 1994-08-12 Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta Expired - Lifetime DE69434593D1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10612093A	1993-08-13	1993-08-13
US23816994A	1994-05-04	1994-05-04
PCT/US1994/009193 WO1995005191A1 (en)	1993-08-13	1994-08-12	METHODS AND COMPOSITIONS FOR STIMULATING AND INHIBITING TGF-β ACTIVITY

Publications (1)

Publication Number	Publication Date
DE69434593D1 true DE69434593D1 (de)	2006-02-02

Family

ID=26803316

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69434593T Expired - Lifetime DE69434593D1 (de)	1993-08-13	1994-08-12	Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta

Country Status (8)

Country	Link
US (1)	US6384189B1 (de)
EP (1)	EP0716609B1 (de)
JP (1)	JPH09505555A (de)
AT (1)	ATE314394T1 (de)
AU (1)	AU697624B2 (de)
CA (1)	CA2169360A1 (de)
DE (1)	DE69434593D1 (de)
WO (1)	WO1995005191A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5932545A (en) *	1997-03-17	1999-08-03	Abbott Laboratories	Antiangiogenic drug to treat cancer, arthritis and retinopathy
ATE280781T1 (de) *	1997-03-17	2004-11-15	Abbott Lab	Antiangiogene substanz zur behandlung von krebs, arthritis und netzhauterkrankungen
US6525023B1 (en)	1997-08-13	2003-02-25	Kyowa Hakko Kogyo Co., Ltd.	Vascular smooth muscle cell growth factor
US6989435B2 (en)	1997-09-11	2006-01-24	Cambridge University Technical Services Ltd.	Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en)	1997-09-11	2006-06-27	Cambridge University Technical Services, Ltd.	Compounds and methods to inhibit or augment an inflammatory response
US6121236A (en) *	1998-03-24	2000-09-19	The Children's Medical Center Corporation	Multivalent ligands which modulate angiogenesis
US7238711B1 (en)	1999-03-17	2007-07-03	Cambridge University Technical Services Ltd.	Compounds and methods to inhibit or augment an inflammatory response
CA2697598A1 (en) *	1999-01-12	2000-07-20	Cambridge Enterprise Limited	Compounds and methods to inhibit or augment an inflammatory response
GB9915311D0 (en) *	1999-06-30	1999-09-01	Isis Innovation	Modulation of dendritic cell maturation
ITMI20010995A1 (it)	2001-05-15	2002-11-15	Getters Spa	Dispensatori di cesio e processo per il loro uso
JP2007502623A (ja) *	2003-05-09	2007-02-15	リサーチディベロップメントファウンデーション	膜タンパク質におけるフリンプロテアーゼ開裂部位の挿入およびその使用法
CA2613193A1 (en) *	2005-06-24	2007-01-04	Ramtin Agah	Thrombospondin-1 derived peptides and treatment methods
US9614220B2 (en)	2007-01-29	2017-04-04	Umicore	Doped and island-covered lithium cobaltite oxides
EP2340034B2 (de) *	2008-08-07	2019-02-13	The United States Of America, As Represented By The Secretary, Department of Health and Human Services	Strahlenschutzmittel mit thrombospondin-1 und cd47 als target
EP2836591B1 (de)	2012-04-09	2018-06-06	The United States of America, as represented by The Secretary, Department of Health and Human Services	Verfahren zur erzeugung pluripotenter und multipotenter zellen
KR101594032B1 (ko) *	2012-08-23	2016-02-15	강원대학교산학협력단	염증 또는 피부노화의 예방 또는 치료용 약학 조성물 및 염증 또는 피부노화 개선용 화장료 조성물
US11285169B2 (en)	2013-03-13	2022-03-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods for modulating chemotherapeutic cytotoxicity
EP2994156A4 (de) *	2013-05-10	2017-01-11	Southern Research Institute	Verbindungen, zusammensetzungen und verfahren zur behandlung von erkrankungen durch hemmung der tgf-aktivität
FR3024364B1 (fr)	2014-07-31	2016-09-02	Neuronax	Oligopeptides particuliers comme medicaments anti-angiogeniques

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2085865T3 (es) *	1988-06-30	1996-06-16	Astra Ab	Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
US5028425A (en) *	1988-07-07	1991-07-02	The United States Of America As Represented By The Department Of Health And Human Services	Synthetic vaccine against P. falciparum malaria
US5192744A (en)	1990-01-12	1993-03-09	Northwestern University	Method of inhibiting angiogenesis of tumors
US5190918A (en)	1990-02-22	1993-03-02	W. R. Grace & Co.-Conn.	Peptide fragments and analogs of thrombospondin and methods of use
US5674503A (en) *	1990-07-24	1997-10-07	University Of Victoria	Peptides capable of eliciting an immune response to leishmaniasis and methods of using the same
US5824647A (en) *	1990-12-12	1998-10-20	Postlethwaite; Arnold E.	Chemotactic wound healing peptides
US5357041A (en) *	1991-12-06	1994-10-18	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin
US5770563A (en) *	1991-12-06	1998-06-23	The United States Of America As Represented By The Department Of Health And Human Services	Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
EP0673384A4 (de) *	1992-12-10	1996-10-09	Univ Minnesota	Polypeptide nützlich in der behandlung von entzündlichen erkrankungen.
US5561107A (en) *	1993-06-04	1996-10-01	Demeter Biotechnologies, Ltd.	Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides

1994
- 1994-08-12 AU AU75652/94A patent/AU697624B2/en not_active Ceased
- 1994-08-12 CA CA002169360A patent/CA2169360A1/en not_active Abandoned
- 1994-08-12 DE DE69434593T patent/DE69434593D1/de not_active Expired - Lifetime
- 1994-08-12 WO PCT/US1994/009193 patent/WO1995005191A1/en active IP Right Grant
- 1994-08-12 AT AT94925878T patent/ATE314394T1/de not_active IP Right Cessation
- 1994-08-12 JP JP7507120A patent/JPH09505555A/ja not_active Ceased
- 1994-08-12 EP EP94925878A patent/EP0716609B1/de not_active Expired - Lifetime
1997
- 1997-06-10 US US08/871,561 patent/US6384189B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2169360A1 (en)	1995-02-23
WO1995005191A1 (en)	1995-02-23
EP0716609A1 (de)	1996-06-19
ATE314394T1 (de)	2006-01-15
EP0716609B1 (de)	2005-12-28
AU7565294A (en)	1995-03-14
EP0716609A4 (de)	1998-01-07
AU697624B2 (en)	1998-10-15
JPH09505555A (ja)	1997-06-03
US6384189B1 (en)	2002-05-07

Legal Events

Date	Code	Title	Description
2006-11-30	8332	No legal effect for de

Publication	Publication Date	Title
DE69434593D1 (de)	2006-02-02	Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta
DE69636997D1 (de)	2007-05-10	HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
EP0692483A4 (de)	1995-11-29	Zelladhäsionsinhibitor und thienotriazoldiazepin-derivat
ES2082198T3 (es)	1996-03-16	Inhibidores de esteroide-sulfatasa.
ATE241358T1 (de)	2003-06-15	Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69429450D1 (de)	2002-01-24	Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung
DE60029799D1 (de)	2006-09-14	Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE277612T1 (de)	2004-10-15	Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE346600T1 (de)	2006-12-15	Inhibierung der p38 kinase-aktivität durch die verwendung von aryl- und heteroarylsubstituierten harnstoffen
ATE347366T1 (de)	2006-12-15	Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
DE69924615D1 (de)	2005-05-12	Thymosin beta 4 stimuliert wundheilung
ATE287717T1 (de)	2005-02-15	Verwendung eines oestrogens zur verhütung und behandlung von ischaemischer schädigung
DE122011100032I1 (de)	2012-05-16	Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
DE60040753D1 (de)	2008-12-18	Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
DE69533704D1 (de)	2004-12-02	Bradykinin-antagonist peptide mit n-substituierten glycinen
ATE320814T1 (de)	2006-04-15	Verwendung von zinkhyaluronat gegen magengeschwür
ATE217514T1 (de)	2002-06-15	Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
ATE453402T1 (de)	2010-01-15	Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69716460D1 (de)	2002-11-21	Wundheilung und behandlung von fibrose
ATE230609T1 (de)	2003-01-15	Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
IS4847A (is)	1998-09-15	Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni
DK0671909T3 (da)	2001-03-19	Syndecanstimulering af cellulær differentiering
DE69924979D1 (de)	2005-06-02	Behandlung von chronischen schmerzen
DE69429013D1 (de)	2001-12-13	Verwendung von dimeticon zur behandlung der konstipation
FR2720938B1 (fr)	1996-08-30	Composition dermato-cosmétologique et son utilisation.